Novartis meningitis B vaccine Bexsero® receives FDA Breakthrough Therapy designation in the US

The designation highlights the potential of Bexsero to meet the urgent need for a licensed vaccine in the US against unpredictable and devastating meningitis B Bexsero, already approved in Europe, Canada and Australia, is the only broad coverage meningitis B vaccine that can be used from two months of age Bexsero was recently provided to two US universities under an …